Inflammation is a relevant treatment target in osteoarthritis
- PMID: 37839421
- DOI: 10.1016/S0140-6736(23)01726-9
Inflammation is a relevant treatment target in osteoarthritis
Conflict of interest statement
I received consulting fees from Pfizer, Galapagos, Jansen, CHDR, Novartis, and UCB, which were paid to the Department of Rheumatology, Leiden University Medical Center.
Comment on
-
Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial.Lancet. 2023 Nov 11;402(10414):1764-1772. doi: 10.1016/S0140-6736(23)01572-6. Epub 2023 Oct 12. Lancet. 2023. PMID: 37839420 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
